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A few weeks ago, after many years of intensive work, the
much-awaited fifth edition of the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-5) was published.
It is still the case today that psychiatric diagnoses seem to
be more consensus-based than validity-based (Cuthbert
and Insel 2013; Bschor et al. 2012; Berk 2013) - something
that DSM-5 will also be unable to change. In spite of this,
DSM-5 introduces several important changes with regard
to diagnostic criteria for bipolar disorders. The Inter-
national Journal of Bipolar Disorders is honored that Jules
Angst, whose work has made an outstanding contribution
to the modifications regarding bipolar disorders in DSM-5
(Angst et al. 2011, 2012), has agreed to comment on the
strengths, problems and perspectives relating to these
changes in the paper that accompanies this editorial
(Angst 2013).
An essential topic thankfully addressed by Jules Angst
in the accompanying paper (Angst 2013) has been hotly
debated within the psychiatric scientific community
throughout the last few years - namely whether bipolar
disorders are much more frequent than previously
assumed. If this is the case, one may conclude that the
hitherto existing diagnostic criteria have falsely prevented
the proper diagnosis of all cases of bipolar disorders on
account of their being overly restrictive.
In DSM-5, bipolar and related disorders, as they are
now called, are given a chapter on their own, between
depressive disorders and schizophrenia spectrum disor-
ders, that includes bipolar I disorder (which represents,
according to DSM-5, classic manic depressive disorder,
with the exception that neither a depressive episode nor
psychosis has to be present for diagnosis), bipolar II
disorder and cyclothymic disorder. Furthermore, in this
chapter, there are now separate diagnostic criteria for* Correspondence: Emanuel.Severus@uniklinikum-dresden.de
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reproduction in any medium, provided the orig“manic-like phenomena” associated with the use of
substances (either substances of abuse or prescribed medi-
cations) or with medical conditions. Finally, to encourage
further study, as the DSM-5 explicitly states, bipolar-like
phenomena that do not fulfill the diagnostic criteria for
bipolar I disorder, bipolar II disorder or cyclothymic
disorder (i.e. short-duration hypomanic episodes and major
depressive episodes, hypomanic episodes with insufficient
symptoms and major depressive episodes, hypomanic
episode without prior major depressive episode, and short-
duration cyclothymia) are summarized under the label
“other specified bipolar and related disorders”.
Given these changes, DSM-5 seems to concur with the
idea that there has been an under-recognition of bipolar
disorders. However, in return, the obligatory symptoms
(gate A criteria) which have to be present to fulfill the
criteria for a hypomanic or manic episode have been
specified. While in the past only a distinct period of
abnormally and persistently elevated, expansive or
irritable mood was necessary, these symptoms now have
to be present in combination with persistently increased
(goal-directed) activity or energy, most of the day, nearly
every day. While some disagree with this step, for under-
standable reasons (Angst et al. 2011, 2012), we feel that
this is a wise approach, in particular with regard to the
diagnosis of bipolar II disorder. Why do we feel this way?
Bipolar II disorder is the only psychiatric disorder
which is typically characterized by the absence of the
critical constituent, i.e. the hypomanic episode, at the
time of diagnosis. The diagnosis is most often assigned
to young patients presenting with a (first) major depres-
sive episode. In these cases, diagnosis is exclusively
based on psychiatric history taken, not on current psy-
chopathological assessment by the psychiatrist. However,
any retrospective recall is prone to recall bias. This may
be even more significant during a depressive episode. In
addition, with a hypomanic episode, there is a condition
at stake which, by definition, is insufficiently severe to
cause (significant) impairment in social or occupationalhis is an Open Access article distributed under the terms of the Creative
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level of creativity. Consequently, a hypomanic episode is
frequently judged by the patient as being ego-syntonic.
Therefore, finding out whether, at some point in the past,
there has been a change in mood, associated with an
unequivocal change in functioning, that is uncharacteristic
of the individual when not symptomatic may significantly
depend on the information provided by others, such as
close friends, relatives or partners. Unfortunately, the
information provided by these others is rarely gathered in
scientific studies involving issues related to making the
diagnosis of bipolar II disorder. A change in mood in the
direction of elevated mood, for example, is primarily a
subjective experience, not necessarily associated with an
unequivocal change in functioning - and thereby not
necessarily easily accessible to others. In contrast, (hypo)
mania-associated change in mood, by definition, has to be
accompanied by an unequivocal change in functioning.
Therefore, a further specification of the change in mood
with which (hypo)mania is associated is clearly needed.
From a clinical point of view, this change in mood is
well captured by the term “hyper” (which is, inciden-
tally, the screening question for (hypo)mania in SCID
for DSM-IV). Being hyper invariably includes being
highly energetic. Therefore, from a clinician and DSM
perspective, it is a completely logical and consistent
step to formally add increase in (goal-directed) activity/
energy to the change in mood as a gate A criterion
in DSM-5.
While diagnoses may have diverse functions (e.g. as a
tool for communication about features/symptoms or as
justification for claiming of benefits and reimbursements
in the healthcare system), informing treatment decisions
is one of the most crucial (Cuthbert and Insel 2013). In
the clinical example described above (a young patient
with a first major depressive episode), whether a diagno-
sis of major depressive disorder or bipolar II disorder is
made will have a large and significant impact on the
future treatment, and especially the long-term treatment.
According to current treatment guidelines, a young
patient with a first major depressive episode in the con-
text of a major depressive disorder will likely be treated
with an antidepressant for a period of 6 to 12 months,
depending on a variety of (clinical) variables, such as
severity of the depressive episode or family history
(Bauer et al. 2013). In contrast, a patient with the diag-
nosis of bipolar depression will probably be treated with
either quetiapine or a combination of an antidepressant
and a prophylactic antimanic agent (sometimes referred
to as a “mood stabilizer”) (Pfennig et al. 2012). Quetiapine
or the mood stabilizer, if effective, will be given until
further notice. One of the criteria for efficacy will be the
prevention of new hypomanic/manic episodes. Now, if we
think of diagnostic criteria as a “type of test for theunderlying, etiologically defined, illness”, lowering the
diagnostic threshold for bipolar disorders, as proposed by
some, will increase the probability of false positives and
reduce the probability of false negatives, and vice versa
(Zimmerman 2012). With regard to our example, a young
patient with a major depressive episode who is falsely di-
agnosed with a bipolar disorder (whereas in reality he/she
is suffering from unipolar depression) will be treated with
a prophylactic antimanic agent (mood stabilizer) and this
treatment may continue indefinitely as one of the criteria
for efficacy will be the prevention of new manic episodes -
which the patient will not develop as he/she is, in reality,
suffering from unipolar depression. In contrast, if a patient
with a major depressive episode is falsely diagnosed with
major depressive disorder, whereas, in reality, the patient
is suffering from bipolar II disorder (as the most probable
case), the patient will be treated with an antidepressant
(which, according to a recent expert survey, is a legitimate
treatment option for bipolar II disorder) (Pacchiarotti
et al. 2013). If the patient does not respond to the anti-
depressant, it will be augmented with lithium, quetiapine,
aripiprazole or olanzapine (Bauer et al. 2013). Lithium,
quetiapine, aripiprazole and olanzapine are all prophylactic
antimanic agents (mood stabilizers), and the combination
of an antidepressant and a prophylactic antimanic agent is
a viable treatment option for long-term treatment in
patients with bipolar II disorder (Pacchiarotti et al. 2013).
Alternatively, if such a patient develops a hypomanic or
manic episode during antidepressant monotherapy, which
continues for a substantial period of time after cessation of
the antidepressant, a diagnosis of bipolar disorder will be
made according to the current DSM-5 criteria, and the
individual will be treated accordingly. Therefore, in terms
of the requirement to “do no harm”, the consequences of
being falsely diagnosed with bipolar disorders tend to be
more severe than those of being falsely diagnosed with
major depressive disorder (Frances and Jones 2012). In
addition, if the goal of diagnosis is not only to inform
current treatment decisions but also to contribute in deve-
loping future treatment options, having patients with
falsely diagnosed bipolar disorders in genome-wide asso-
ciation studies (GWAS) may cloud statistically significant
associations - and thereby prohibit the development of
tailored personalized treatment options, based on the
findings of these GWAS, for patients with bipolar disorders
(Schulze 2010).
In summary, in our view, the DSM-5 criteria nicely
specify what is currently understood by the diagnosis of
“bipolar disorders” (with the current treatment options
based upon these definitions) and at the same time
allow further exploration of the nature of disorders (e.g.
in terms of treatment response) which, at this point
in time, have to be referred to as disorders related to
bipolar disorders.
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